News | September 18, 2012

Neovasc Announces Publication of Tiara Transcatheter Mitral Valve Preclinical Data in JACC

Chronic animal studies underway in preparation for potential first human implantations in 2013

Tiara transcatheter mitral valve

The Tiara transcatheter mitral valve.


September 18, 2012 — Neovasc Inc. announced that acute results from preclinical studies of its Tiara valve for the transcatheter treatment of mitral regurgitation were published in the Journal of the American College of Cardiology (JACC). The study reports that the initial experience with the Tiara transcatheter mitral valve was encouraging, and that implantation of Tiara valves was feasible, relatively straightforward and resulted in a securely-implanted, well-functioning device that maintained good hemodynamics in the test animals. The study, which will be published in the Oct. 9, 2012, edition of JACC, is currently available online.

We are very pleased with the results of our Tiara implantations in preclinical animal models,” noted Alexei Marko, CEO of Neovasc. “Publication of the first results from the acute phase of these studies in a prestigious journal such as JACC highlights the potential value of Tiara for the treatment of patients with mitral regurgitation who cannot be treated surgically. We look forward to sharing long-term Tiara results from studies in chronic animal models at TCT 2012 next month.”

In the published study, Tiara valves were implanted successfully in 81 percent of the test animals, with total procedure times ranging from 17 to 26 minutes.  In the successful implantations, angiographic and echo imaging demonstrated excellent function of the Tiara, with no obstruction of the left ventricular outflow tract, no pericardial effusion, no encroachment on the aortic valve, no transvalvular gradients and most importantly, no significant paravalvular leak.  All animals remained hemodynamically stable during the implant procedure without the need for rapid pacing.

The report, "Tiara: A Novel Catheter-Based Mitral Valve Bioprosthesis: Initial Experiments and Short-Term Pre-Clinical Results," was authored by Shmuel Banai, M.D., E. Marc Jolicoeur, M.D., Marc Schwartz , RCIS, Patrick Garceau, M.D., Simon Biner, M.D., Jean-Francois Tanguay, M.D., Raymond Cartier, M.D., Stefan Verheye, M.D., Christopher J. White, M.D. and Elazer Edelman, M.D., Ph.D.  It is being published in the Journal of the American College of CardiologyVol. 60, No. 15, 2012

For more information: content.onlinejacc.org/article.aspx?articleid=1358177


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now